Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TB-QUEST

Financiado

Questioning the Epidemiology of Subclinical Tuberculosis

Tuberculosis (TB) remains a major cause of morbidity and mortality around the world. The majority of TB control policies rely on the binary paradigm of TB, which focus on interventions tackling ‘latent’ TB infection and ‘active’ T... ver más

30/04/2029

FUNDACION PRIVADA...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL B... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 27M€

Ver 3 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-04-18

ERC-2023-STG: ERC STARTING GRANTS Scope:Objectives

I+D

Cerrada hace 2 años

0% 100% 100%

3 Participantes

FUNDACION PRIVADA INSTITUTO...

1.57M€ | Lider

925.00K€ | Participante

HOSPITAL CLINIC DE BARCELONA

112.50K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PCIN-2013-041 UNA APROXIMACION OMICA AL DIAGNOSTICO DE LA TUBERCULOSIS Cerrado

JCI-2009-05713 Identificación y caracterización de cepas y variantes de Myc... 101K€ Cerrado

PID2019-104477RB-I00 PREDICIENDO GENOTIPOS EXITOSOS DE MYCOBACTERIUM TUBERCULOSIS... 303K€ Cerrado

BES-2014-071066 TRANSFORMANDO LAS NUEVAS TECNOLOGIAS DE SECUENCIACION EN UNA... Cerrado

SAF2013-43521-R TRANSFORMANDO LAS NUEVAS TECNOLOGIAS DE SECUENCIACION EN UNA... Cerrado

SAF2017-84839-C2-1-R EL FENOTIPO SILENTE DE MYCOBACTERIUM TUBERCULOSIS: PERSISTEN... 109K€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2024-04-18
Fecha Fin: 2029-04-30

Líder del proyecto

FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL B... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 27M€

Presupuesto del proyecto 2M€

Descripción del proyecto Tuberculosis (TB) remains a major cause of morbidity and mortality around the world. The majority of TB control policies rely on the binary paradigm of TB, which focus on interventions tackling ‘latent’ TB infection and ‘active’ TB disease stages. However, recent evidence disputes this longstanding conceptualization of TB natural history, demonstrating that TB exists on a continuous spectrum of bacterial and immunological responses. Several active case-finding studies have shown that around 50% of the cases in whom Mycobacterium tuberculosis was isolated in sputum were asymptomatic. Subclinical (asymptomatic) TB has lately attracted increased scientific interest since it could play an important role in TB transmission, despite the absence of cough. However, beyond limited evidence on TB transmission based on modelling studies using retrospective data collection, there is not a single field study showing a direct transmission from an index subclinical TB case to a secondary laboratory-confirmed case. If subclinical TB does spread the disease, the consequences for global TB control and research are of paramount importance. I propose to characterize the subclinical TB stage within the natural history of TB and to understand its role in spreading the disease. I have designed a field epidemiological study (TB-QUEST) with the potential to show evidence of effective transmission from subclinical TB cases to close contacts, using pathogen genome sequencing. Additionally, by using innovative wearable technology, I will assess whether objective tools to measure classical TB symptoms match the self-reported absence of symptoms. Thus, I might challenge the current definition of subclinical TB and the usefulness of current TB screening algorithms. Lastly, I will study the clinical trajectory of subclinical TB in order to improve our understanding of its natural history, duration of infectiousness, and factors associated with self-clearance or progression to symptomatic disease.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores